After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.

Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a phase 2 candidate in the fiercely competitive IgA nephropathy (IgAN) category.